Highest-materiality recent filing
Bone Biologics raises $3M, extends runway to Q2 2027, advances NB1 study
Completed $3.0M private placement with healthcare-focused institutional investor; warrants could add up to $6.0M if exercised.
Bone Biologics postpones 2026 annual meeting to September 28, 2026
Annual meeting moved from August 11 to September 28, 2026; new record date August 6, 2026.
Bone Biologics prices $3.0M private placement with up to $6.0M in warrant proceeds
Gross proceeds of ~$3.0M from sale of 2,112,677 pre-funded warrants and Series F/G warrants at $1.419 per unit.
Bone Biologics files prospectus supplement for ATM offering of up to $1.064M in common stock
Filing covers up to $1,064,000 shares of common stock sold at market through H.C. Wainwright as sales agent.
Extended validated shelf life of rhNELL-1 protein product candidate to 24 months (prior 12/18 months).
Bone Biologics CEO updates on NB1 trial enrollment, shelf life extension, and $5M offering
Clinical trial enrollment slower than anticipated; expects to complete enrollment by year-end 2025.
Bone Biologics closes $5M public offering, net proceeds ~$4.3M
Gross proceeds $5M from 1.25M shares (or pre-funded) plus Series D/E warrants; net ~$4.3M after fees.
Bone Biologics regains Nasdaq minimum bid price compliance
Received Nasdaq notice on June 25, 2025 confirming compliance with Listing Rule 5550(a)(2).
Bone Biologics announces 1-for-6 reverse stock split effective June 10, 2025
Reverse stock split ratio of 1-for-6, effective 12:01 a.m. ET on June 10, 2025.
Bone Biologics shareholders approve 30M share increase and 1-for-2.5 to 1-for-10 reverse split
Stockholders elected directors Stroever, Angle, Gagnon, and Meikle; all received >90% of votes cast (excluding broker non-votes).
Bone Biologics receives Nasdaq delisting notice for bid price below $1; plans reverse stock split
Received Nasdaq deficiency letter on April 7, 2025 for failing minimum bid price of $1 per share for 30 consecutive business days.
Bone Biologics sets 2025 annual meeting for May 30; shareholder proposals due April 11
2025 Annual Meeting on May 30, 2025; record date and proposals to be detailed in proxy statement.
Bone Biologics updates ATM offering limit to $832,009 after $846k previously sold
Filed prospectus supplement resetting ATM with H.C. Wainwright to max $832,009 in common shares.
Bone Biologics appoints Phillip Meikle to board, replacing retiring director Don Hankey
Phillip Meikle appointed to Bone Biologics board effective October 16, 2024.
Director Don Hankey resigns from Bone Biologics board effective Oct 1, 2024
Don Hankey resigned as director of Bone Biologics effective October 1, 2024.
Bone Biologics enters ATM equity offering agreement with H.C. Wainwright for up to $1.14M
Entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell common stock shares from time to time.
Bone Biologics stockholders elect directors, approve exec comp, ratify auditor at annual meeting
Don Hankey, Bruce Stroever, Siddhesh Angle, and Robert Gagnon elected directors at Sept. 17, 2024 annual meeting.
Bone Biologics raises $2.1M via exercise of warrants, issues new warrants for 1.56M shares
Existing warrant holders exercised 781,251 shares at $2.43/share, yielding ~$2.1M gross proceeds.
First two patients treated in pilot study of NB1 bone graft device for spine fusion
Two patients treated in Australia in multicenter pilot study evaluating NB1 (NELL-1+DBM) for TLIF in degenerative disc disease.
Bone Biologics enters amended CEO agreement with $300K salary, transaction bonus provision
CEO Jeffrey Frelick receives $300,000 annual base salary, bonus target of 50% of salary, and transaction bonus of 1-2% of deal value upon acquisition.
Bone Biologics closes $2.0M public offering of shares and warrants; net proceeds ~$1.5M
Priced 119,000 shares and 662,251 pre-funded warrants, each with warrants to buy one share at $2.43.
Bone Biologics reports NB1 clinical trial progress: 3 sites engaged in Australia
NB1 pilot trial: 30 adults, randomized, evaluating safety & effectiveness in TLIF for DDD.
Bone Biologics settles breach-of-contract lawsuit for $750,000 cash payment
Company will pay plaintiffs $750,000 cash within 20 business days of the January 9, 2024 effective date.
Bone Biologics appoints Robert Gagnon to board of directors, replacing Erick Lucera
Robert Gagnon appointed to board effective Jan 8, 2024; Erick Lucera resigned same date.
Bone Biologics regains Nasdaq minimum bid price compliance; stock continues listing
Received Nasdaq notice confirming compliance with minimum bid price rule (Rule 5550(a)(2)).
Bone Biologics director Erick Lucera resigns pending successor appointment
Erick Lucera resigned as director effective upon appointment of a new director.
Bone Biologics announces 1-for-8 reverse stock split effective December 20
Reverse stock split at 1-for-8 ratio effective 12:01 a.m. ET on December 20, 2023.
Stockholders approve reverse stock split; Nasdaq grants continued listing until Jan 12, 2024
Stockholders voted 1,402,685 for, 162,168 against, 16,129 abstain to authorize reverse stock split at ratio 1:5 to 1:20.
Bone Biologics announces registered direct offering of 1.14M shares at $0.64/share, with warrants
Gross proceeds ~$729,200; net proceeds ~$591,000 after fees.
Bone Biologics reduces stockholder quorum requirement from majority to one-third
Board approved Bylaw Amendment reducing quorum from majority to at least one-third of outstanding voting power.
Bone Biologics receives Nasdaq delisting notice for bid price non-compliance
Received Nasdaq staff determination to delist due to failure to maintain $1.00 minimum bid price.
Bone Biologics stockholders elect directors and approve all proposals at annual meeting
Four director nominees elected: Hankey, Stroever, Lucera, Angle; broker non-votes of 578,270 for each.
Nasdaq confirms Bone Biologics compliance with minimum bid price; one-year panel monitor imposed
Received letter from Nasdaq Hearings Advisor on June 28, 2023 confirming compliance with Listing Rule 5550(a)(2) for minimum bid price.
Bone Biologics prices $5M underwritten public offering of 2.5M shares at $1.97/share
Gross proceeds of approximately $5.0 million from sale of 2,538,071 shares of common stock at $1.97 per share.
Bone Biologics effects 1-for-30 reverse stock split effective June 5, 2023
1-for-30 reverse split of common stock and warrants effective June 5, 2023; par value unchanged.
Bone Biologics receives Nasdaq delisting notice; plans appeal and reverse stock split
Nasdaq notified BBLG on May 18, 2023 that its common stock and warrants are subject to delisting for failing to maintain $1.00 bid price.
Director Stephen LaNeve resigns from Bone Biologics board
Stephen LaNeve resigned as a director effective December 18, 2022.
Bone Biologics receives Nasdaq delisting notice for bid price non-compliance
Received Nasdaq notice on Nov 17, 2022: common stock closing bid below $1.00 for 30 consecutive business days.
Raised $5.1M gross in underwritten public offering of common stock and warrants for clinical trials and working capital.
Bone Biologics closes $5.1M public offering of 3.78M units at $1.35/unit
Gross proceeds of $5.1M from offering of 3,777,778 units at $1.35 per unit.
Bone Biologics prices $5.1M public offering of 3.78M units at $1.35/unit
Gross proceeds $5.1M from sale of 3,777,778 units; net proceeds estimated ~$4.454M.
Elected directors Don Hankey, Stephen La Neve, Bruce Stroever, Erick Lucera, Siddhesh Angle with ~7.3M votes each; 666,720 broker non-votes.
Bone Biologics amends license with UCLA, deferring $8M diligence fee tied to future sales milestones
Third Amendment extends development milestones; UCLA defers $8M diligence fee until first sale of licensed product.
Bone Biologics sets 2022 Annual Meeting for August 23; stockholder proposal deadline June 23
2022 Annual Meeting scheduled for August 23, 2022; record date June 24, 2022.
Bone Biologics secures exclusive DBM supply from MTF for rhNELL-1 spine fusion product
Exclusive supply agreement with MTF Biologics for demineralized bone matrix (DBM) as carrier for rhNELL-1 bone graft substitute.
Bone Biologics enters revised employment agreement with CFO, base salary $200K
Employment agreement effective Jan 3, 2022; at-will; base salary $200,000.
Bone Biologics closes $7.9M public offering, uplists to Nasdaq Capital Market
Completed public offering of 1,510,455 units at $5.25/unit for gross proceeds of $7.9M.
Bone Biologics prices $7.9M public offering, uplists to Nasdaq, effects 1-for-2.5 reverse split
Offering of 1,510,455 units at $5.25/unit raised $7.9M gross; units consist of 1 share + 1 warrant (strike $6.30, 5-year term).
On October 16, 2024, the Board of Directors (the “Board”) of Bone Biologics Corporation (the “Company”) appointed Phillip Meikle to the Company’s Board.
On October 1, 2024, Don Hankey informed Bone Biologics Corporation (the “Company”) of his resignation as a director of the Company effective immediately.
On January 8, 2024, the Board of Directors of Bone Biologics Corporation (the “Company”) appointed Robert E. Gagnon to the Company’s Board of Directors.
As previously disclosed, Erick Lucera resigned from the Board of Directors on December 27, 2023, effective as of the date Mr. Gagnon was appointed.
On December 27, 2023 Erick Lucera resigned as a director of the Company, effective upon the appointment of a new director.
Effective December 18, 2022 Stephen LaNeve resigned as a director of the Company.
Max materiality 0.85 · Median 0.55 · Most common event other_material